fashion -WSS

fashion

author：explore 2025-10-02 19:38:37 - browse：6

Daphne Koller -- biotech coverage from STAT — Daphne Koller, early biotech AI entrant Insitro's founder, CEO and board member. Courtesy Jerrick Mitra/Insitro

New artificial intelligence technologies made headlines last year for their ability to do everything from generating fake musical duets to understanding how proteins fold. But in biotech, one of the most well-funded AI players has been quiet.

Insitro, a South San Francisco firm, was founded in 2018 by Daphne Koller, who had previously been a Stanford professor, a 2004 MacArthur “genius” grant recipient, and the co-founder and co-CEO of the online course company Coursera. It raised more than $643 million in venture capital, according to PitchBook, from investors including T. Rowe Price, ARCH Venture Partners, and Casdin Capital. The company now has more than 260 employees spread out over 107,000 square feet of laboratory and office space.

But what exactly is Koller building?

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

hotspot

WSS

'Reaching a detente': STAT's Helen Branswell on covering Covid

DOJ, FTC to increase scrutiny of all types of health care mergers

Researchers separate signal from noise in heart wearable data

Biden's 'march

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

Stanford updates investigation of president’s past research

Wikipedia

fashion

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The untold story of TV’s first prescription drug ad

Virginia high school admissions case could be legal follow

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Fetal cell organoids grown from amniotic fluid, study finds

Psychedelics group wrestles with new pharma identity

The kidney, in all its complexity, is captured in a new atlas

Tori Bowie and the unacceptable rates of Black maternal death

Medicare drug price negotiation continues, as pharma counteroffers

knowledge

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Norman Reedus' Daryl Dixon

Plane’s emergency slide plummets from sky, hits Chicago home

Longer MASH drug regimen improved liver, Akero study finds

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Pregnant women don't need prenatal multivitamins, study concludes

focus

hotspot

leisure time

explore